Posts made in October, 2016

Vol. 42 N. 06, 2016

Int Braz J Urol. Vol. 42 N. 06 – 2016

Download the PDF file .

EDITORIAL In this issue

1056 | Penile Cancer: The Importance to predict lymph node metastasis

Luciano A. Favorito [view article]


1058 | Data vs Dogma in Peyronie’s Disease

Ryan P. Terlecki, Alison M. Rasper [view article]


1062 | MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes

Ronaldo Hueb Baroni [view article]

1065 | MRI should be routine for all patients with localized prostate cancer? | Opinion: No

Joel B. Nelson [view article] Read More

Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis

Vol. 42 (x): 2016 September 5.[Ahead of print]

doi: 10.1590/S1677-5538.IBJU.2016.0483


Arie Carneiro 1,2, Willy Baccaglini 2, Felipe P.A. Glina 3, Paulo P. Kayano 1, Victor M. Nunes 4, Oren Smaletz 5, Wanderley Marques Bernardo 4, Icaro Thiago de Carvalho 6, Gustavo Caserta Lemos 1

1 Departamento de Urologia, Hospital Israelita Albert Einstein, SP, Brasil; 2 Departamento de Urologia, Faculdade de Medicina do ABC, SP, Brasil; 3 Faculdade de Ciências Médicas, Universidade Metropolitana de Santos, SP, Brasil; 4 Centro Universitário Lusiada, Faculdade de Ciências Médicas de Santos, SP, Brasil; 5 Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brasil; 6 Departamento de Radioterapia, Hospital Israelita Albert Einstein, São Paulo, Brasil



Context: Currently, standard treatment of metastatic prostatic cancer (MPCa) is androgen-deprivation therapy (ADT). Recent studies suggested that local treatment of MPCa is related to increase of survival of those patients, as observed in other tumors.

Objective: To evaluate the impact of local treatment on overall survival and cancer specific survival in 3 and 5 years in patients with MPCa.

Materials and Methods: Systematic review and meta-analysis of population studies published at PubMed, Scielo, Lilacs, Cochrane and EMBASE databases until June 2016. Several large cohorts and Post-Roc studies were included, that evaluated patients with MPCa submitted to local treatment (LT) using radiotherapy (RDT), surgery (RP) or brachytherapy (BCT) or not submitted to local treatment (NLT).


Read More

Robot-assisted laparoscopic radical prostatectomy with early retrograde release of the neurovascular bundle and endopelvic fascia sparing

Vol. 42 (x): 2016 May 4.[Ahead of print]

doi: 10.1590/S1677-5538.IBJU.2015.0349


George Augusto Monteiro Lins de Albuquerque 1,2, Giuliano Betoni Guglielmetti 1,2, Maurício Dener Cordeiro 1,2, William Carlos Nahas 1,2, Rafael Ferreira Coelho 1,2

1 Instituto do Câncer de São Paulo, SP. Brasil; 2 Divisão de Urologia, Faculdade de Medicina, Universidade de São Paulo, SP, Brasil


Introduction: Robotic-assisted radical prostatectomy (RAP) is the dominant minimally invasive surgical treatment for patients with localized prostate cancer. The introduction of robotic assistance has the potential to improve surgical out­comes and reduce the steep learning curve associated with conventional laparoscopic radical prostatectomy. The purpose of this video is to demonstrate the early retrograde release of the neurovascular bundle without open the endopelvic fascia during RAP.

Materials and Methods: A 51-year old male, presenting histological diagnosis of prostate adenocarcinoma, Gleason 6 (3+3), in 4 cores of 12, with an initial PSA=3.41ng/dl and the digital rectal examination demonstrating a prostate with hardened nodule in the right lobe of the prostate base (clinical stage T2a). Surgical treatment with the robot-assisted technique was offered as initial therapeutic option and the critical technical point was the early retrograde release of the neurovascular bundle with endopelvic fascia preservation, during radical prostatectomy.

Results: The operative time was of 89 minutes, blood loss was 100ml. No drain was left in the peritoneal cavity. The patient was discharged within 24 hours. There were no intraoperative or immediate postoperative complications. The pathological evaluation revealed prostate adenocarcinoma, Gleason 6,...

Read More

Prostate cancer screening in Brazil: should it be done or not?

Vol. 42 (6): 1069-1080, November – December, 2016

doi: 10.1590/S1677-5538.IBJU.2015.0709


Wilson F. S. Busato Jr 1, Gilberto L. Almeida 1,2

1 Departamento de Urologia, UNIVALI –Itajai, SC, Brasil; 2 Instituto Catarinense de Urologia, Itajaí, SC, Brasil


The use of PSA in the screening, detection and prognosis of prostate cancer (PCa) has revolutionized the diagnosis and treatment of this disorder with an increase in detection rates and PCa organ-confined. Despite these benefits and ease of implementation, tracking PCa remains a matter of great controversy. We conducted a literature review and demographic and epidemiological data in Brazil feeling to assess the current state of screening and whether there is justification for population programs. the diferences are valued between developed and underdeveloped countries as the incidence, mortality, screening and access to health. an analysis of the advantages and disadvantages of screening is made as well as a critical analysis of existing studies on screening and some recommendations on a rational screening.

Keywords: Prostatic Neoplasms; Mass Screening; Brazil

[Full Text]

Prostate cancer in Brazil and Latin America: epidemiology and screening

Vol. 42 (6): 1081-1090, November – December, 2016

doi: 10.1590/S1677-5538.IBJU.2015.0690


Rafael Rocha Tourinho-Barbosa 1, Antonio Carlos Lima Pompeo 1, Sidney Glina 1

1 Departamento Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil


Introduction: Prostate cancer is one of the tumors with higher incidence and mortality among men in the World. Epidemiological data are influenced by life expectancy of population, available diagnostic methods, correct collection of data and quality of health services. Screening of the disease is not standardized around the World. Up till now there is no consensus about the risks versus benefits of early detection. There are still missing data about this pathology in Latin America.

Objective: to revise current epidemiologic situation and early diagnosis policies of prostate cancer in Brazil and Latin America.

Materials and Methods: Medline, Cochrane Library and SciELO databases were reviewed on the subject of epidemiology and screening of prostate cancer. Screening research was performed in websites on national public health organizations and Latin America. Screening recommendations were obtained from those governmental organizations and from Latin American urological societies and compared to the most prominent regulatory agencies and societies of specialists and generalists from around the World.

Results: Brazil and Latin America have a special position in relation to incidence and mortality of prostate cancer. In Brazil, it occupies the first position regarding incidence of cancer in men and the second cause of mortality. Central America has the highest rate of mortality of the continent with lower...

Read More